Literature DB >> 19914397

Progress towards personalized medicine.

Stewart Bates1.   

Abstract

Personalized medicine is the tailoring of therapies to defined subsets of patients based on their likelihood to respond to therapy or their risk of adverse events. The advent of improved genomic tools has greatly hastened our understanding of the molecular pathology of diseases, enabling us to redefine disease at the molecular level. The development of molecularly targeted therapies, coupled with improved diagnostic criteria, holds the promise of delivering a new paradigm in drug development. But how far have we come, and how close is personalized medicine to delivering on its promise? Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914397     DOI: 10.1016/j.drudis.2009.11.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  25 in total

1.  Structural requirements of research tissue banks derived from standardized project surveillance.

Authors:  E Herpel; N Koleganova; B Schreiber; B Walter; C V Kalle; P Schirmacher
Journal:  Virchows Arch       Date:  2012-06-01       Impact factor: 4.064

Review 2.  Development and applications of photo-triggered theranostic agents.

Authors:  Prakash Rai; Srivalleesha Mallidi; Xiang Zheng; Ramtin Rahmanzadeh; Youssef Mir; Stefan Elrington; Ahmat Khurshid; Tayyaba Hasan
Journal:  Adv Drug Deliv Rev       Date:  2010-09-19       Impact factor: 15.470

3.  Drug discovery: engineering drug combinations.

Authors:  Scott J Dixon; Brent R Stockwell
Journal:  Nat Chem Biol       Date:  2010-05       Impact factor: 15.040

4.  RNA-stabilized whole blood samples but not peripheral blood mononuclear cells can be stored for prolonged time periods prior to transcriptome analysis.

Authors:  Svenja Debey-Pascher; Andrea Hofmann; Fatima Kreusch; Gerold Schuler; Beatrice Schuler-Thurner; Joachim L Schultze; Andrea Staratschek-Jox
Journal:  J Mol Diagn       Date:  2011-07       Impact factor: 5.568

Review 5.  Biobanking residual tissues.

Authors:  Peter H J Riegman; Evert-Ben van Veen
Journal:  Hum Genet       Date:  2011-08-04       Impact factor: 4.132

6.  Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.

Authors:  Jacob Nersting; Louise Borst; Kjeld Schmiegelow
Journal:  Clin Proteomics       Date:  2011-06-03       Impact factor: 3.988

7.  Translation in Data Mining to Advance Personalized Medicine for Health Equity.

Authors:  Estela S Estape; Mary Helen Mays; Elizabeth A Sternke
Journal:  Intell Inf Manag       Date:  2016-01

8.  Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs.

Authors:  Jeanette K Birnbaum; Foluso O Ademuyiwa; Josh J Carlson; Leslie Mallinger; Mark W Mason; Ruth Etzioni
Journal:  Med Decis Making       Date:  2015-08-24       Impact factor: 2.583

9.  Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis.

Authors:  Benjamin M Craig; Gang Han; Murat K Munkin; David Fenstermacher
Journal:  Stat Methods Med Res       Date:  2013-03-15       Impact factor: 3.021

10.  Personalized cardiac regeneration by stem cells-Hype or hope?

Authors:  Ulrich Marc Becher; Vedat Tiyerili; Dirk Skowasch; Georg Nickenig; Nikos Werner
Journal:  EPMA J       Date:  2011-03-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.